Annual SG&A
$1.21 M
-$761.40 K-38.68%
31 December 2023
Summary:
Protagenic Therapeutics annual selling, general & administrative expenses is currently $1.21 million, with the most recent change of -$761.40 thousand (-38.68%) on 31 December 2023. During the last 3 years, it has fallen by -$644.70 thousand (-34.81%). PTIX annual SG&A is now -96.78% below its all-time high of $37.47 million, reached on 31 December 2007.PTIX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$287.90 K
-$165.40 K-36.49%
30 September 2024
Summary:
Protagenic Therapeutics quarterly selling, general & administrative expenses is currently $287.90 thousand, with the most recent change of -$165.40 thousand (-36.49%) on 30 September 2024. Over the past year, it has dropped by -$19.80 thousand (-6.43%). PTIX quarterly SG&A is now -98.03% below its all-time high of $14.64 million, reached on 31 March 2008.PTIX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$132.14 M
-$5.65 M-4.46%
30 September 2024
Summary:
Protagenic Therapeutics TTM selling, general & administrative expenses is currently -$132.14 million, with the most recent change of -$5.65 million (-4.46%) on 30 September 2024. Over the past year, it has dropped by -$133.54 million (-9506.87%). PTIX TTM SG&A is now -42411.34% below its all-time high of $50.17 million, reached on 30 June 2008.PTIX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTIX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.7% | -6.4% | -9506.9% |
| 3 y3 years | -34.8% | -43.2% | -4846.9% |
| 5 y5 years | -15.8% | +81.6% | -9623.5% |
PTIX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -59.8% | at low | -59.7% | +43.4% | -68.6% | at low |
| 5 y | 5 years | -59.8% | at low | -75.4% | +81.6% | -135.7% | at low |
| alltime | all time | -96.8% | +1600.1% | -98.0% | +102.9% | <-9999.0% | +81.1% |
Protagenic Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $287.90 K(-36.5%) | $1.22 M(-1.6%) |
| June 2024 | - | $453.30 K(+63.3%) | $1.24 M(+13.3%) |
| Mar 2024 | - | $277.60 K(+38.2%) | $1.09 M(-9.4%) |
| Dec 2023 | $1.21 M(-38.7%) | $200.80 K(-34.7%) | $1.21 M(-14.1%) |
| Sept 2023 | - | $307.70 K(+0.1%) | $1.40 M(-7.6%) |
| June 2023 | - | $307.40 K(-21.4%) | $1.52 M(-10.0%) |
| Mar 2023 | - | $391.30 K(-1.8%) | $1.69 M(-14.2%) |
| Dec 2022 | $1.97 M(-34.5%) | $398.30 K(-5.8%) | $1.97 M(-13.8%) |
| Sept 2022 | - | $422.70 K(-11.2%) | $2.29 M(-3.6%) |
| June 2022 | - | $476.20 K(-29.1%) | $2.37 M(-22.6%) |
| Mar 2022 | - | $671.40 K(-6.1%) | $3.06 M(+1.9%) |
| Dec 2021 | $3.00 M(+62.2%) | $714.70 K(+41.0%) | $3.00 M(+7.9%) |
| Sept 2021 | - | $506.90 K(-56.6%) | $2.78 M(-1.6%) |
| June 2021 | - | $1.17 M(+90.3%) | $2.83 M(+34.9%) |
| Mar 2021 | - | $613.80 K(+24.1%) | $2.10 M(+8.2%) |
| Dec 2020 | $1.85 M(+44.9%) | $494.80 K(-10.4%) | $1.94 M(+16.4%) |
| Sept 2020 | - | $552.20 K(+26.4%) | $1.67 M(+31.0%) |
| June 2020 | - | $436.90 K(-3.9%) | $1.27 M(+4.7%) |
| Mar 2020 | - | $454.80 K(+105.7%) | $1.21 M(-5.0%) |
| Dec 2019 | $1.28 M(-10.8%) | $221.10 K(+39.5%) | $1.28 M(-7.9%) |
| Sept 2019 | - | $158.50 K(-58.3%) | $1.39 M(-11.3%) |
| June 2019 | - | $380.00 K(-26.7%) | $1.56 M(+1.9%) |
| Mar 2019 | - | $518.60 K(+57.0%) | $1.54 M(+7.1%) |
| Dec 2018 | $1.43 M(-13.0%) | $330.40 K(-1.4%) | $1.43 M(-4.7%) |
| Sept 2018 | - | $335.00 K(-4.6%) | $1.50 M(-2.7%) |
| June 2018 | - | $351.30 K(-15.6%) | $1.54 M(-0.0%) |
| Mar 2018 | - | $416.30 K(+3.8%) | $1.54 M(-6.2%) |
| Dec 2017 | $1.65 M(+27.2%) | $400.90 K(+6.5%) | $1.65 M(-4.4%) |
| Sept 2017 | - | $376.40 K(+7.1%) | $1.72 M(+1.9%) |
| June 2017 | - | $351.40 K(-32.3%) | $1.69 M(+9.4%) |
| Mar 2017 | - | $519.10 K(+8.8%) | $1.55 M(+18.9%) |
| Dec 2016 | $1.30 M(+163.9%) | $477.00 K(+38.7%) | $1.30 M(+33.5%) |
| Sept 2016 | - | $344.00 K(+66.9%) | $974.20 K(+28.2%) |
| June 2016 | - | $206.10 K(-24.5%) | $760.20 K(+13.8%) |
| Mar 2016 | - | $273.10 K(+80.9%) | $668.10 K(+29.5%) |
| Dec 2015 | - | $151.00 K(+16.2%) | $516.00 K(+2.8%) |
| Sept 2015 | - | $130.00 K(+14.0%) | $502.00 K(+2.4%) |
| June 2015 | $491.00 K(-49.6%) | $114.00 K(-5.8%) | $490.00 K(-8.4%) |
| Mar 2015 | - | $121.00 K(-11.7%) | $535.00 K(-33.5%) |
| Dec 2014 | - | $137.00 K(+16.1%) | $804.00 K(-10.6%) |
| Sept 2014 | - | $118.00 K(-25.8%) | $899.00 K(-7.9%) |
| June 2014 | $975.00 K(+28.6%) | $159.00 K(-59.2%) | $976.00 K(+19.5%) |
| Mar 2014 | - | $390.00 K(+68.1%) | $817.00 K(+91.3%) |
| Dec 2013 | - | $232.00 K(+19.0%) | $427.00 K(+119.0%) |
| Sept 2013 | - | $195.00 K(-92.7%) | $195.00 K(-98.2%) |
| June 2013 | $758.00 K(-94.2%) | - | - |
| Sept 2011 | - | $2.69 M(-11.5%) | $10.78 M(-7.3%) |
| June 2011 | - | $3.03 M(+12.4%) | $11.63 M(-6.5%) |
| Mar 2011 | - | $2.70 M(+14.5%) | $12.43 M(-5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | $13.12 M(-43.2%) | $2.36 M(-33.3%) | $13.12 M(-19.0%) |
| Sept 2010 | - | $3.54 M(-7.9%) | $16.20 M(-12.4%) |
| June 2010 | - | $3.84 M(+13.3%) | $18.49 M(-9.5%) |
| Mar 2010 | - | $3.39 M(-37.6%) | $20.43 M(-11.5%) |
| Dec 2009 | $23.09 M(-11.3%) | $5.43 M(-6.7%) | $23.09 M(+125.0%) |
| Sept 2009 | - | $5.83 M(+0.8%) | $10.26 M(-20.7%) |
| June 2009 | - | $5.78 M(-4.5%) | $12.95 M(-27.2%) |
| Mar 2009 | - | $6.05 M(-181.8%) | $17.77 M(-32.6%) |
| Dec 2008 | $26.03 M(-30.5%) | -$7.39 M(-186.9%) | $26.36 M(-44.5%) |
| Sept 2008 | - | $8.51 M(-19.8%) | $47.47 M(-5.4%) |
| June 2008 | - | $10.61 M(-27.5%) | $50.17 M(+7.7%) |
| Mar 2008 | - | $14.64 M(+6.7%) | $46.60 M(+25.4%) |
| Dec 2007 | $37.47 M(+125.0%) | $13.71 M(+22.3%) | $37.15 M(+58.5%) |
| Sept 2007 | - | $11.21 M(+59.3%) | $23.43 M(+91.5%) |
| June 2007 | - | $7.04 M(+35.7%) | $12.24 M(-362.6%) |
| Mar 2007 | - | $5.19 M(>+9900.0%) | -$4.66 M(+3.4%) |
| Dec 2006 | $16.65 M(>+9900.0%) | - | - |
| Oct 2006 | - | $14.40 K(-100.1%) | -$4.51 M(+0.8%) |
| July 2006 | - | -$9.86 M(-285.1%) | -$4.47 M(-183.0%) |
| July 2006 | $71.00 K(-24.9%) | - | - |
| Apr 2006 | - | $5.33 M(>+9900.0%) | $5.39 M(+8866.9%) |
| Jan 2006 | - | $9700.00(-80.8%) | $60.10 K(+19.2%) |
| Oct 2005 | - | $50.40 K(-97.1%) | $50.40 K(-99.3%) |
| July 2005 | $94.50 K(-98.9%) | - | - |
| Apr 2003 | - | $1.75 M(+8.8%) | $7.38 M(-5.5%) |
| Jan 2003 | - | $1.61 M(-9.4%) | $7.81 M(-6.3%) |
| Oct 2002 | - | $1.77 M(-21.3%) | $8.33 M(-2.6%) |
| July 2002 | $8.55 M(-0.7%) | $2.25 M(+3.5%) | $8.55 M(-0.8%) |
| Apr 2002 | - | $2.18 M(+2.1%) | $8.62 M(+0.4%) |
| Jan 2002 | - | $2.13 M(+7.0%) | $8.59 M(-1.1%) |
| Oct 2001 | - | $1.99 M(-14.2%) | $8.68 M(+0.8%) |
| July 2001 | $8.61 M(+10.8%) | $2.32 M(+8.5%) | $8.61 M(+4.4%) |
| Apr 2001 | - | $2.14 M(-3.9%) | $8.25 M(+0.5%) |
| Jan 2001 | - | $2.23 M(+15.7%) | $8.21 M(+4.1%) |
| Oct 2000 | - | $1.92 M(-1.6%) | $7.88 M(+0.3%) |
| July 2000 | $7.77 M(-3.8%) | $1.96 M(-6.9%) | $7.86 M(-0.3%) |
| Apr 2000 | - | $2.10 M(+10.6%) | $7.88 M(-1.2%) |
| Jan 2000 | - | $1.90 M(0.0%) | $7.98 M(0.0%) |
| Oct 1999 | - | $1.90 M(-4.0%) | $7.98 M(-1.2%) |
| July 1999 | $8.08 M(+16.3%) | $1.98 M(-10.0%) | $8.08 M(+1.7%) |
| Apr 1999 | - | $2.20 M(+15.8%) | $7.95 M(+3.9%) |
| Jan 1999 | - | $1.90 M(-5.0%) | $7.65 M(+4.1%) |
| Oct 1998 | - | $2.00 M(+8.3%) | $7.35 M(+4.3%) |
| July 1998 | $6.95 M(+6.9%) | $1.85 M(-2.8%) | $7.05 M(+5.2%) |
| Apr 1998 | - | $1.90 M(+18.8%) | $6.70 M(+4.7%) |
| Jan 1998 | - | $1.60 M(-5.9%) | $6.40 M(-3.0%) |
| Oct 1997 | - | $1.70 M(+13.3%) | $6.60 M(+34.7%) |
| July 1997 | $6.50 M | $1.50 M(-6.3%) | $4.90 M(+44.1%) |
| Apr 1997 | - | $1.60 M(-11.1%) | $3.40 M(+88.9%) |
| Jan 1997 | - | $1.80 M | $1.80 M |
FAQ
- What is Protagenic Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Protagenic Therapeutics?
- What is Protagenic Therapeutics annual SG&A year-on-year change?
- What is Protagenic Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly SG&A year-on-year change?
- What is Protagenic Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Protagenic Therapeutics?
- What is Protagenic Therapeutics TTM SG&A year-on-year change?
What is Protagenic Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of PTIX is $1.21 M
What is the all time high annual SG&A for Protagenic Therapeutics?
Protagenic Therapeutics all-time high annual selling, general & administrative expenses is $37.47 M
What is Protagenic Therapeutics annual SG&A year-on-year change?
Over the past year, PTIX annual selling, general & administrative expenses has changed by -$761.40 K (-38.68%)
What is Protagenic Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of PTIX is $287.90 K
What is the all time high quarterly SG&A for Protagenic Therapeutics?
Protagenic Therapeutics all-time high quarterly selling, general & administrative expenses is $14.64 M
What is Protagenic Therapeutics quarterly SG&A year-on-year change?
Over the past year, PTIX quarterly selling, general & administrative expenses has changed by -$19.80 K (-6.43%)
What is Protagenic Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of PTIX is -$132.14 M
What is the all time high TTM SG&A for Protagenic Therapeutics?
Protagenic Therapeutics all-time high TTM selling, general & administrative expenses is $50.17 M
What is Protagenic Therapeutics TTM SG&A year-on-year change?
Over the past year, PTIX TTM selling, general & administrative expenses has changed by -$133.54 M (-9506.87%)